Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

earch, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $10.3 million and $3.6 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

At September 30, 2013, the Company had cash and equivalents of $78.9 million, compared to $17.5 million at December 31, 2012.  The increase of $61.4 million was primarily due to the completion of an initial public offering that raised net proceeds of $58.1 million and to the completion of a concurrent private offering that raised net proceeds of $25.1 million, less cash used to fund operations.

The Company expects its research and development expense to increase as it prepares for the initiation of the Phase 3 clinical trial of quizartinib in relapsed or refractory AML patients, which is expected to begin early in 2014.  Under the base case operating plan, which assumes that the FDA will require a randomized, controlled Phase 3 clinical trial for an NDA submission, the Company currently expects cash and cash equivalents to be sufficient to fund this trial and operations through the receipt of top line data from the Company's Phase 3 trial in approximately 326 relapsed/refractory AML patients. 

Conference Call and Webcast
A conference call hosted by the Ambit management team will be webcast live today at 2pm PT or 5pm ET and can be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify that you would like to join the "Ambit Third Quarter 2013 Earnings Conference Call" and reference conference ID number 35424048.  If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday,
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 26, 2015 , ... Lee Biosolutions, a global biotech healthcare ... of highly valued cardiac markers used in early detection of heart disease due ... has led to the development and commercialization of important cardiac biomarkers used in ...
(Date:8/26/2015)... JERUSALEM and BEIJING , August 26, ... Startup Scene with Impressive Acheivements  DiaCardio wins 1 st ...   The competition, led in Israel ... ‎, featured 21 startups from countries including the US, ... and Latin America .  ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial Management ... local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to introduce ... pathways., , Stem Cell Meeting on the Mesa ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently installed ... company has added a AS16 Sharples centrifuge to harvest products after fermentation. The ... fungal fermentation process development. , The new centrifuge greatly expands production capabilities ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New centrifuge and fermentor expand product development capacity at Vets Plus 2
... Host Update Conference Call Today at 8:30 a.m. EST, ... RIGL ) today reported financial results for,the three and ... quarter of 2008, Rigel reported a net loss of $37.7,million, ... $18.9 million, or,$0.61 per share, in the third quarter of ...
... Inc. (Nasdaq: VNUS ), a leading provider of ... disease, today,announced the hiring of Guido Smeets, MD, as ... Dr. Smeets joins VNUS with over 17 years of ... the Head of Clinical Affairs for,Pelikan Technologies, Inc., a ...
... Calif., Oct. 31 SleepQuest has always,followed the essence ... suffer from,undiagnosed and unexplained health problems related to lack ... discuss the,importance of identifying and treating sleep disorders. Sleep ... as a wellness factor.,Studies done by the National Commission ...
Cached Biology Technology:Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 2Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 3Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 4Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 5Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 6VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer 2SleepQuest Tireless in Pursuit of Good Sleep 2
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... Aug. 5, 2015 The biosensors market is ... applications, penetration into newer sectors, and development of devices ... biosensors space has seen the entry of multiple participants ... far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( http://www.frost.com/nee9 ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... Researchers at Wayne State University have discovered a ... undergoing hemodialysis that may prevent cardiovascular disease common in ... at a greater risk for atherosclerosis, a common disease ... can lead to serious problems including heart attack, stroke ...
... KAN. -- People who decrease sitting time and increase ... according to Kansas State University research. Even standing ... at a time -- can improve health and quality ... such as cardiovascular disease, diabetes, heart disease, stroke, breast ...
... initiative bridges the gap between research and the market. ... processes that protect the environment become fully-fledged commercial prospects, ... new product is intended for the aeronautic market, where ... to conventional Cr-based coatings, which provide optimum corrosion protection, ...
Cached Biology News:Wayne State discovers potential treatment for better heart health in hemodialysis patients 2Take a stand and be active to reduce chronic disease, make aging easier, research finds 2The Eco-Innovation initiative rewards ideas for innovative products that protect the environment 2
... Immunogen: Synthetic peptide derived from the ... Specificity: Specific for the junctophilin-1 ... mouse brain and skeletal muscle homogenates ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
Request Info...
Laminin beta-1/gamma-1 (612C10)...
HSV 1 IgM...
Biology Products: